
AI in Dermatology: A Systematic Review on Skin Cancer Detection

Safrian Andromeda¹, Ni Luh Bella Dwijaksana².

safrian@ft.unsika.ac.id¹, nfebriyanti@ft.unsika.ac.id².

Electrical Engineering, Universitas Singaperbangsa Karawang, West Java, Indonesia.

ABSTRACT

Skin cancer is the most common type of cancer worldwide and poses a significant public health challenge. Its visible nature often leads individuals to seek medical attention, highlighting the importance of early detection for better patient outcomes. In recent years, Artificial Intelligence (AI) has shown promise in improving the detection and diagnosis of skin cancer, offering the potential to enhance clinical outcomes. A systematic review was conducted, involving a comprehensive literature search to identify studies focused on AI techniques in detecting, diagnosing, or treating skin cancer. Strict inclusion and exclusion criteria were applied to assess the eligibility of scientific articles, resulting in the selection of nine relevant studies. These studies were analyzed to address predefined research questions about the effectiveness of AI in diagnosing skin cancer. The review found that AI-assisted clinicians achieved higher sensitivity and specificity in diagnosing skin cancer than those without assistance. Various AI algorithms demonstrated high sensitivity in detecting skin cancers, highlighting their potential to support primary care clinicians in evaluating suspicious lesions. The analysis also highlighted the effectiveness of smartphone applications designed for skin cancer risk assessment, which could facilitate self-examinations and enhance early detection rates. Despite these promising findings, the field of AI in skin cancer diagnosis is still in its early stages. Challenges remain, including developing robust algorithms, addressing data quality issues, and improving the interpretability of AI-generated results. Collaboration between AI developers and healthcare professionals is crucial to ensure these tools' clinical effectiveness and safety. The review emphasizes the need for continued validation of AI technologies and their integration into clinical practice to improve patient outcomes and alleviate the burden on healthcare systems.

Keywords: AI; Dermatology; Detection; Skin Cancer.

Article Info

Accepted : 18-06-2024

This is an open-access article under the [CC BY-SA](#) license.

Revised : 03-04-2024

Published Online : 25-06-2024



Correspondence Author:

Safrian Andromeda
Electrical Engineering,
Universitas Singaperbangsa Karawang,
Jl. HS.Ronggo Waluyo, Puseurjaya, Telukjambe Timur, Karawang, Jawa Barat 41361
Email: safrian@ft.unsika.ac.id

1. INTRODUCTION

The skin is the body's largest organ and is vital in protecting internal organs and performing various functions. It is connected to the mucous membranes at the openings of the digestive, respiratory, and urogenital systems. Skin disorders are often the main reason people seek medical help due to their visible nature. Among these disorders, skin cancer is hazardous and life-threatening [1].

Skin cancer is a condition marked by the uncontrolled growth of skin cells [2]. Skin cancer is a significant cause of cancer-related deaths globally, with the World Health Organization (WHO) estimating over 60,000 deaths annually from melanoma alone [3]. Australia has one of the highest rates of skin cancer in the world. The reported incidence of skin cancer is four times higher than in the United States, the United Kingdom, and Canada. However, a significant number of skin cancer cases are also found in the United States. On the other hand, Indonesia has a relatively low number of skin cancer cases compared to those countries. However, it is important to understand that skin cancer can lead to disfigurement, affecting appearance, and in advanced stages, it can be fatal [1].

Indonesia, a tropical country located along the equator, receives very high levels of sunlight exposure. This exposure to sunlight is a significant risk factor for skin cancers. Genetics, melanin levels, and UV wavelength influence the risk. UV rays can cause DNA photoproducts, which, if not repaired, can lead to errors in DNA replication, mutations in cellular signaling molecules, and, ultimately, cancer development. UVB rays (wavelength: 280-320 nm) are considered 1,000 times more damaging per photon than UVA (320-400 nm). UVA exposure in the environment is 20 to 40 times higher, depending on the time of day, season, latitude, and altitude. UVA has also been found to cause oxidative damage to DNA [4]. In Indonesia, melanoma ranks as the 23rd most common cancer, with approximately 1,609 new cases and around 699 deaths reported annually, indicating a fatality rate exceeding 50% of new cases. The rising prevalence and high mortality associated with skin cancer highlight the urgent need for effective prevention strategies and public health initiatives to address this escalating global health concern [3].

Melanoma represents a severe variant of skin cancer that may arise from pre-existing moles, which can present as either black or similar to the surrounding skin tone. Alterations in the size or texture of a mole, including growth or ulceration, may indicate the presence of melanoma. Individuals with a personal history of melanoma, numerous moles, compromised immune systems, or frequent exposure to ultraviolet radiation should prioritize regular dermatological evaluations. This type of cancer has the potential to metastasize to other regions of the skin and internal organs, frequently occurring on the face or body, particularly on the lower legs in women. Recognizing that melanoma can also develop in areas not typically exposed to sunlight is essential. The disease originates from melanocytes, the cells that generate skin pigment. Although early detection and intervention are generally adequate for most skin cancers, malignant melanoma presents a more formidable challenge [5].

The traditional method for detecting skin cancer involves a visual examination and assessment of the skin by healthcare professionals. This process utilizes the ABCDE rule, which stands for Asymmetry, Border irregularity, Color variation, Diameter larger than 6mm, and Evolving changes in size, shape, or color of moles or skin lesions [3]. A visual inspection is typically the first step in diagnosing skin cancer. The Skin Cancer Foundation and the American Cancer Society recommend monthly self-examinations and yearly doctor appointments to check for potential skin cancer. If a suspicious spot is discovered, the doctor will inspect the area, noting the size, shape, color, and texture of the lesion, as well as any bleeding or scaling. Additionally, the doctor might check the nearby lymph nodes for any enlargement. If being evaluated by a primary care physician, a dermatologist can conduct more advanced testing and provide a diagnosis. Dermoscopy, a procedure dermatologists use to examine concerning spots carefully, may involve a specialized microscope or magnifying lens [6]. Dermatologist diagnosis relies on their visual examination, which can be influenced by various factors such as lighting conditions, experience, and individual judgment. This subjectivity can lead to inconsistencies and errors in skin cancer diagnosis [7].

Traditional methods for detecting skin cancer, such as visual inspection and dermoscopy, have significant limitations due to subjectivity and low sensitivity. Visual examinations by dermatologists, the most common method, achieve about 60% accuracy in melanoma detection, which can increase to 89% with dermoscopy. However, there is still a significant potential for diagnostic error, especially among primary care clinicians. To overcome these challenges, exploring and implementing innovative approaches and technologies to enhance diagnostic capabilities and improve patient outcomes is important [8], [9], [10].

Artificial intelligence (AI) is at the forefront of technological innovation and is present in nearly every industry and field. In dermatology, significant progress has been made in the application of AI for skin cancer screening and diagnosis [11]. AI (Artificial Intelligence) algorithms have shown great promise in diagnosing skin cancer, often performing better than human dermatologists. In several studies, AI achieved higher diagnostic accuracy than dermatologists, outperforming them in 7 out of 11 cases. Additionally, AI algorithms can identify a broader range of clinically relevant diagnoses. Dermatologists with less experience in

dermoscopy benefited the most from using AI, showing the most remarkable improvement in their diagnostic accuracy [8].

Recent advancements in deep learning and image processing techniques have shown promise in improving the accuracy of skin cancer detection [10], [12]. These methods analyze lesion features such as symmetry, color, size, and shape to distinguish between benign and malignant skin cancers [13]. AI-based methods, especially deep learning algorithms, have shown improved accuracy in categorizing skin lesions from various image types, including dermoscopic, clinical, and histopathological images [14]. AI applications in dermatology are mainly centered on creating screening technologies using deep neural networks and supervised learning algorithms. These systems analyze different imaging methods, with dermoscopy and clinical images being the most prevalent [15]. AI has demonstrated potential in improving diagnostic accuracy for both dermatologists and non-specialists, as well as enabling patient self-screening [11]. Recent research has emphasized the development, implementation, and validation of AI systems in clinical settings. Studies have explored various data processing techniques and model architectures [16]. A more accurate assessment of suspicious skin lesions by general practitioners could reduce unnecessary referrals and biopsies, enhancing the patient experience while lowering demand and costs for dermatology specialist services. More precise assessments could also lead to earlier skin cancer diagnoses, improving patient outcomes. There is growing evidence that artificial intelligence and machine learning (AI/ML) can aid clinicians in making better clinical decisions or even substitute human judgment. Studies have demonstrated that AI/ML algorithms can perform as well as, or better than, consultant dermatologists in diagnosing skin cancers, offering significant support to clinicians in their diagnostic processes [17].

Artificial intelligence (AI) can potentially enhance skin cancer detection and diagnosis. Studies have shown that AI-assisted clinicians achieve higher sensitivity (81.1%) and specificity (86.1%) in comparison to unassisted clinicians (74.8% and 81.5%, respectively) in diagnosing skin cancer [18]. An elastic scattering spectroscopy device utilizing AI algorithms demonstrated high sensitivity (97.04%) in the detection of various skin cancers, potentially assisting primary care clinicians in evaluating suspicious lesions [19]. AI can aid in diagnosing skin cancer risk through automated image analysis, pattern recognition, and machine learning, allowing non-experts to make assessments [20]. While AI has the potential to revolutionize early skin cancer detection, it is crucial to validate these tools and collaborate with healthcare professionals to ensure clinical effectiveness and safety [16]. Even though AI cannot fully replace doctors in integrating patient history with physical examination findings [21]. The field is still in its early stages, with most research remaining in the feasibility study phase, and it still needs to progress to practical clinical implementation. Ongoing challenges include developing robust algorithms, addressing data quality issues, and improving result interpretability [22]. Collaboration between AI developers and healthcare professionals is essential for ensuring clinical effectiveness and safety [16].

Artificial intelligence (AI) presents a promising alternative, offering a non-invasive and objective method for diagnosing skin cancer. Although AI has yet to be widely recognized among dermatologists in Indonesia, they must become familiar with this technology as it advances. In recent years, the use of AI in dermatology, particularly for skin cancer diagnosis, has garnered significant attention. This systematic literature review aims to explore the role and advancements of AI in aiding skin cancer diagnosis, evaluate the effectiveness of various algorithms, and highlight the potential limitations. Additionally, it seeks to identify opportunities for enhancing diagnostic support tools to assist clinicians in improving patient outcomes and reducing the burden on healthcare systems.

2. RESEARCH METHOD

In this study, a systematic literature review (SLR) method is used to study and understand information related to the main objectives and topics of the research. The SLR is organized based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The method consists of three phases: planning, conducting, and reporting (Fig. 1). In the planning phase, the context for article searches and the formulation of research questions, which will serve as the foundation for the literature review, are determined. The next phase involves searching for reference materials or literature sources (search process). The final phase is reporting and concluding the results of the proposed research activities and discussions.

2.1 Research Questions

The list of research questions can be derived from the research needs regarding the discussed topic. Here is the list of research questions in this literature review:

1. RQ1: What is the research object in the article?
2. RQ2: What development methods are used to apply AI in Skin Cancer?
3. RQ3: In what activities is AI commonly used in Skin Cancer?




Figure 1. Steps of a Systematic Literature Review

2.2 Search Process

Systematic Literature Review (SLR)

A Systematic Literature Review (SLR) is a structured and methodological approach to research that aims to collect, identify, evaluate, and critically synthesize all relevant studies related to a specific topic or research question. This process is carried out systematically by following established steps and protocols to ensure objectivity, transparency, and comprehensiveness in reviewing the existing literature. Through an SLR, researchers can obtain a comprehensive overview of the state of the art in a particular field, identify research gaps, and formulate recommendations for future research based on the synthesis of previous study findings. Therefore, an SLR is not just a narrative review but a structured and guided research method that provides a deep understanding of a research topic [23].

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

Initially released in 2009, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) aimed to help researchers transparently report the reasons for conducting systematic reviews, the processes undertaken by the authors, and the findings obtained. As the methodology and terminology in systematic reviews have evolved over the past decade, the guidelines needed updating to align with these advancements. The PRISMA 2020 statement is an update of the previous version released in 2009. This new guideline includes reporting instructions adjusted to the latest developments in methodology for identifying, selecting, evaluating, and synthesizing relevant studies. The structure and presentation of the items have been modified to facilitate more straightforward implementation [24].

Watase UAKE

Watase.web.id is an online collaborative research system launched in 2018. The system's development started in 2020, involving researchers from various universities. The main goal of www.watase.web.id is to facilitate and simplify researchers in conducting collaborative research with their colleagues from different institutions. Through Watase.web.id, researchers can share information, data, and resources related to their research with other researchers within the system. One of the main features developed is the systematic literature search using the PRISMA method, which assists researchers in conducting comprehensive and structured literature reviews [25].

In addition, Watase.web.id offers a simple meta-analysis feature, allowing researchers to combine data from various studies and analyze it integratively. An article classification feature is also available, helping researchers categorize and organize literature relevant to their research topics. Watase.web.id is equipped with advanced data visualization features to facilitate data interpretation and the discovery of new insights. With these features, researchers can present their data in graphs, diagrams, or other visual representations that are easier to understand and interpret [26].

In this study, the process of collecting references is carried out using the Watase UAKE application. The keywords used in searching related articles are "Skin Cancer using AI." Researchers use the Watase UAKE application generated with an API Key from the Scopus search engine to conduct the literature search. The choice of the Scopus search engine aims to obtain scientific literature with a good reputation and indexed in quartiles Q1, Q2, Q3, and Q4. This search process resulted in findings of 24 articles relevant to the research topic, with publication years ranging from 2019 to 2024.

.




Figure 2. Skin Cancer Tag from Watase UAE

2.3 Determining Inclusion and Exclusion Criteria

The next step is determining the inclusion and exclusion criteria to assess the eligibility of scientific articles for review. The selected article eligibility study is as follows in Tabel 1.

Tabel 1. Inclusion and Exclusion Criteria		
Criteria	Inclusion	Exclusion
Study Focus	<ul style="list-style-type: none"> Studies on AI techniques in skin cancer detection, diagnosis, or treatment. Research evaluating AI tools or algorithms for skin cancer. Studies comparing AI with traditional diagnostic methods. 	<ul style="list-style-type: none"> Studies not involving AI or machine learning in skin cancer. Research focusing on non-technological methods.
Types of Skin Cancer	<ul style="list-style-type: none"> Research addressing melanoma, basal cell carcinoma, squamous cell carcinoma. 	<ul style="list-style-type: none"> Studies not focused on skin cancer.
Publication Type	<ul style="list-style-type: none"> Articles are accessible in full (complete PDF). Open-access articles. Original research articles. 	<ul style="list-style-type: none"> Non articles are accessible in full (complete PDF). Non open-access articles. Non original research articles. Abstracts only.
Publication Date	<ul style="list-style-type: none"> Studies published in the last 5 years. 	<ul style="list-style-type: none"> Studies published more than 5 years ago.
Language	<ul style="list-style-type: none"> Articles published in English. 	<ul style="list-style-type: none"> Articles published in languages other than English.
Technical Scope	<ul style="list-style-type: none"> Studies that apply AI models to clinical practice, including image analysis, diagnosis, or treatment planning. 	<ul style="list-style-type: none"> Research focused solely on the technical development of AI models without application to skin cancer.
Outcome Measures	<ul style="list-style-type: none"> Research that reports on the effectiveness, accuracy, or efficiency of AI in skin cancer diagnostics or treatment. 	<ul style="list-style-type: none"> Studies lacking clear outcome measures or those that do not report the effectiveness of AI applications.

In the keyword search phrase "Skin Cancer using AI" from 2019-2024, 24 relevant articles were found. The articles were 2 in 2019, 2 in 2021, 1 in 2022, 9 in 2023, and 10 in 2024. Next, from the 24 articles, filtering was done based on the quartile, selecting only Quartile 1, the studies included in this review are of the highest quality, relevance, and impact. It enhances the reliability and significance of the review's findings. This approach helps produce a robust synthesis of the most influential research in the field, which is critical for academic and practical advancements, resulting in 13 articles. In the final stage, filtering for fully accessible (complete PDF) and open-access articles resulted in 9 articles.

2.4 Quality Assessment

In this study, the data from the literature review will be evaluated based on quality assessment criteria questions, and each question will be answered as follows:

1. QA1: Was the selected article published between 2019-2024? (Yes(1)/No(0))
2. QA2: Does the selected article discuss the application of AI in the field of Skin Cancer? (Yes(1)/No(0))
3. QA3: Does the selected article describe research development methods for using AI in Skin Cancer? (Yes(1)/No(0))
4. QA4: Does the article specifically mention the use of AI in Skin Cancer? (Yes(1)/No(0))

2.5 Data Analysis

The data collected in the previous stages will be analyzed to answer each predetermined research question.

3. RESULTS AND DISCUSSION

The search process using the keyword "Skin Cancer using AI" for 2019-2024 yielded 24 relevant articles. The distribution of these articles is as follows: 2 articles from 2019, 2 articles from 2021, 1 article from 2022, 9 articles from 2023, and 10 articles from 2024. A further screening based on Quartile ranking was conducted, and only Quartile 1 articles were selected, resulting in 13 articles. In the final stage, the articles were filtered for full-text access (complete PDF), Open Access, and those meeting quality assessment criteria, which resulted in 9 (nine) articles. The search process results are illustrated in (Fig. 3).




Figure 3. Prisma Reporting from Watase UAKE Tools

The quality assessment was conducted based on a quality evaluation (with a total score of 4 (four)) presented in (Table 2).

Table 2. Quality Assessment Results

No	Author	Year	QA1	QA2	QA3	QA4	Result
1	(Midasala et al., 2024)	2024	1	1	1	1	4
2.	(Gaube et al., 2024)	2024	1	1	1	1	4
3.	(Matin & Dinnes, 2021)	2021	1	1	1	1	4
4.	(Barata et al., 2023)	2023	1	1	1	1	4
5.	(Venkatesh et al., 2024)	2024	1	1	1	1	4
6.	(Saeed et al., 2023)	2023	1	1	1	1	4
7.	(Jaklitsch et al., 2023)	2023	1	1	1	1	4
8.	(Marsden et al., 2023)	2023	1	1	1	1	4
9.	(Melarkode et al., 2023)	2023	1	1	1	1	4

After the data selection process, 9 (nine) articles met the inclusion and exclusion criteria and passed the quality assessment stage. These nine articles will be analyzed at this stage to answer each predefined research question. From the obtained articles, several topic ideas emerged, focusing on the discussion of AI in the field of Skin Cancer, including:

1. The Evaluation and Effectiveness of Smartphone Applications Designed for Skin Cancer Risk Assessment

Skin cancer is identified as a significant public health concern, with self-examinations and professional screenings being recommended for early detection. However, these practices are rarely performed by individuals, underscoring the need for more effective screening solutions. The article highlights the potential of mobile health (mHealth) apps that utilize artificial intelligence (AI) to aid skin cancer screening. These apps are designed to assist users in self-examinations, potentially increasing the likelihood of early detection. Despite their promise, the uptake of AI-enabled mHealth apps needs to be higher, raising questions about the factors influencing individuals' decisions to use these apps versus seeking traditional dermatological consultations. The primary aim of the research is to examine the characteristics of both providers (mHealth apps vs. dermatologists) and users that influence the decision-making process regarding skin cancer screening. The study seeks to understand preferences and the reasons for the low adoption of mHealth technology in this context. Additionally, the concept of algorithm aversion is introduced, which refers to the preference for human decision-making over algorithmic solutions, influenced by various factors such as the perceived capabilities of the algorithm and the characteristics of the human provider. Overall, the background sets the stage for exploring the dynamics between technology and user preferences in the context of skin cancer screening, highlighting the need for further research to improve the adoption of AI-enabled health solutions [11].

In transitioning to the technical aspect, machine learning algorithms analyze images of skin lesions to identify patterns associated with malignancy. Techniques include color and symmetry-based analyses, which help in assessing features indicative of skin cancer. While not explicitly mentioned in the excerpts, many AI applications in dermatology often employ deep learning techniques, particularly convolutional neural networks (CNNs), which are effective in image recognition tasks. These networks can learn complex features from large datasets of skin lesion images. Additionally, classification algorithms are used to categorize skin lesions as benign or malignant based on the extracted features, with performance often evaluated in terms of sensitivity (true positive rate) and specificity (true negative rate). This research emphasizes the need for robust evaluation of these algorithms. Many have been developed using biased datasets or under optimal conditions that may not reflect real-world usage—the importance of validating algorithms in diverse and clinically relevant populations to ensure their effectiveness in practice. Several smartphone applications exemplify the integration of AI in practical applications focused on skin cancer risk assessment, explicitly highlighting SkinVision and TeleSkin's skinScan app. SkinVision has undergone multiple studies that report improvements in diagnostic accuracy over time, claiming to assess the risk of skin lesions and showing sensitivity and specificity in identifying malignant or pre-malignant lesions. On the other hand, TeleSkin's skinScan app, designed for skin lesion risk stratification, is available for download, but there is limited published evidence regarding its effectiveness [29].

Furthermore, the discussion extends to a specific type of digital health technology known as Artificial Intelligence as a Medical Device (AIaMD). This technology is designed to analyze dermoscopic images of suspicious skin lesions to identify various types of skin cancer, including non-melanoma skin cancer (NMSC), as well as premalignant and benign lesions. The AIaMD aims to support clinicians in the timely diagnosis and management of skin lesions, enhancing the triage process in dermatology. The DERM-003 study, which is the focus of the journal, utilized smartphone cameras to capture images, demonstrating the feasibility of using widely available digital devices for skin lesion assessment. This approach highlights the integration of AI with digital health tools to improve patient outcomes in dermatological care. Finally, the results of the DERM-003

study indicated that the AI-based digital health technology (AIaMD) demonstrated a high degree of accuracy in identifying skin lesions, particularly squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). The study aimed to achieve co-primary endpoints with an Area Under the Receiver Operator Characteristic (AUROC) curve above 0.9 for both SCC and BCC, suggesting strong diagnostic performance. In total, 572 patients consented to the study, providing 611 suspicious lesions. After exclusions for various reasons, the per protocol (PP) population included a significant number of lesions, with 43 diagnosed as SCC and 176 as BCC by histopathology. The study found that the AIaMD could effectively differentiate between malignant and benign conditions, supporting its potential utility in clinical practice. The statistical analysis showed that the algorithm's confidence scale was closely associated with the histopathology-confirmed diagnoses, indicating that the AIaMD could serve as a reliable tool for dermatologists in diagnosing skin cancer [34].

2. The improvisation AI Application in Detecting Skin Cancer

The journal article discusses using a reinforcement learning (RL) algorithm for AI-based decision support in skin cancer diagnosis. The RL model showed improved sensitivity for melanoma and basal cell carcinoma compared to traditional supervised learning methods. The main finding is that incorporating human preferences into an RL model significantly enhances diagnostic accuracy and management decisions in skin cancer diagnosis compared to a traditional supervised learning (SL) model. Specifically, the RL model achieved increased sensitivity for melanoma, improving from 61.4% (SL model) to 79.5% (RL model), and for basal cell carcinoma, improving from 79.4% (SL model) to 87.1% (RL model). Furthermore, the rate of correct diagnoses made by dermatologists increased by 12.0% with RL model support, and the rate of optimal management decisions improved from 57.4% (without AI support) to 65.3% (with RL model support). These findings suggest that integrating human preferences into AI decision-support systems can lead to better outcomes in clinical practice, particularly in complex scenarios like skin cancer diagnosis [30].

The article also highlights the DermaSensor device, which exemplifies the application of AI in dermatology. The journal article does not specify the algorithm used in the DermaSensor device or other AI-enabled devices discussed. However, it mentions that these devices utilize artificial intelligence (AI) and machine learning (ML) technologies for pattern recognition in dermatology. The focus is on how these technologies can enhance the diagnostic capabilities of primary care physicians by improving sensitivity in detecting skin lesions. Typically, AI algorithms in dermatology may include convolutional neural networks (CNNs) or other deep learning techniques trained on large datasets of skin images to recognize patterns associated with various skin conditions, including skin cancers. For specific details about the algorithm used in DermaSensor, one would need to refer to the manufacturer's documentation or clinical studies that detail the technology behind the device [31].

DermaSensor device utilizes advanced imaging technology and artificial intelligence (AI) to detect skin cancer. Here is a summary of how it operates [31]:

Imaging Technology: DermaSensor employs elastic scattering spectroscopy, which captures detailed images of skin lesions. This technology analyzes the light scattered from the skin to gather information about the tissue's properties.

Data Collection: The device is used by primary care physicians (PCPs) to evaluate skin lesions concerning melanoma, basal cell carcinoma, and squamous cell carcinoma. It collects data from the lesions during the examination.

AI and Machine Learning: The device incorporates AI algorithms that analyze the collected data. These algorithms are trained on large datasets of skin images to recognize patterns associated with different skin lesions. The AI assesses the characteristics of the lesions and provides a risk assessment for malignancy.

Decision Support: The output from DermaSensor is used in conjunction with traditional clinical history and physical examination findings. It helps PCPs decide whether a suspicious lesion should be monitored or referred for further evaluation, such as a biopsy or dermatologist consultation.

The clinical utility of DermaSensor is supported by studies demonstrating its effectiveness in enhancing diagnostic capabilities. Clinical studies have shown that using DermaSensor can increase management sensitivity and diagnostic sensitivity among PCPs, thereby improving their ability to detect skin cancers while reducing false negative referrals. Specifically, the clinical studies supporting the authorization of DermaSensor indicate its effectiveness in enhancing primary care physicians (PCPs) diagnostic capabilities for skin cancer detection. The key findings include increased management sensitivity, with the use of DermaSensor raising sensitivity to 91.4% compared to 82.0% without the device, allowing PCPs to identify better lesions needing further evaluation. Additionally, the diagnostic sensitivity of PCPs using DermaSensor was 81.7%, compared to 71.1% without the device, highlighting the device's role in helping PCPs accurately

identify potentially malignant lesions. Overall, the results suggest that DermaSensor can enhance the diagnostic abilities of PCPs, address access limitations in dermatology, and improve patient outcomes by facilitating earlier detection of skin cancers [31].

The journal highlights how deep learning significantly improved skin cancer classification through various innovative approaches and methodologies. The research utilized advanced Convolutional Neural Networks (CNNs), particularly VGG16 and VGG19, which were recognized for their exceptional performance in image classification tasks. These models were employed to automatically extract features from dermoscopic images of skin lesions, facilitating effective classification without requiring manual feature engineering. Additionally, the study implemented transfer learning techniques, fine-tuning pre-trained weights from models trained on extensive datasets like ImageNet for skin cancer classification. This strategy capitalized on existing knowledge, enhancing the model's performance, particularly when the dataset was limited. Moreover, the research integrated Generative Adversarial Networks (GANs) and Enhanced Super-Resolution Generative Adversarial Networks (ESRGAN) for data augmentation, which generated synthetic images to mitigate class imbalance and enrich the diversity of the training dataset. This augmentation bolstered the model's generalizability and identification of skin lesions. The study also combined CNNs with traditional machine learning classifiers, such as Support Vector Machine (SVM), resulting in a hybrid model (VGG19+SVM) that achieved remarkable performance, with the highest accuracy of 96% on the ISIC 2019 dataset. This combination enhanced feature extraction and classification, thereby improving overall diagnostic capabilities. Furthermore, the research conducted thorough evaluations of different models and augmentation techniques, offering a detailed analysis of their performance, which ensured the identification and application of the most effective methods for skin cancer classification. In summary, the integration of deep learning techniques played a crucial role in significantly enhancing the accuracy and effectiveness of skin cancer classification in this study [32].

The study presented in the journal demonstrates that the system significantly enhances the accuracy and efficiency of skin cancer detection and classification, achieving an impressive classification accuracy of 99.179%. This high performance was rigorously evaluated using the ISIC-2020 dataset, which includes a diverse range of dermoscopic images, ensuring the model's robustness across different skin types and conditions. The research addresses several challenges in skin cancer classification, such as data quality and segmentation accuracy, by incorporating advanced techniques like bilateral filtering for noise reduction, USL-KMC for precise lesion segmentation, and hybrid feature extraction methods (GLCM and RDWT). Additionally, the study emphasizes the importance of interpretability in deep learning models, which is crucial for gaining the trust of healthcare professionals and patients [27].

The main finding of the journal article is that using an AI-powered handheld Elastic Scattering Spectroscopy (ESS) device significantly improves the diagnostic accuracy of primary care physicians (PCPs) when evaluating skin lesions for malignancy. The study reported an increase in the area under the curve (AUC) from 0.62 to 0.68, indicating enhanced clinical utility and better quality of dermatologist referrals. It suggests that incorporating the ESS device into clinical practice can lead to more accurate diagnoses and potentially improve patient outcomes in skin cancer detection. The journal integrates the AI component into the Elastic Scattering Spectroscopy (ESS) device, which utilizes Convolutional Neural Networks (CNNs) alongside spectroscopy technology. The ESS device collects spectral data from skin lesions by analyzing the light scattered from the tissue, providing information about the biochemical composition of the skin. The AI algorithms, particularly CNNs, process this spectral data to identify patterns and features indicative of malignancy. CNNs are particularly effective in recognizing complex patterns in data, which is crucial for distinguishing between benign and malignant lesions. The AI system classifies the lesions as likely benign or malignant based on the extracted features. This classification is then presented to primary care physicians (PCPs) for diagnostic decision-making. Overall, AI enhances the diagnostic process by providing objective data that supports clinical judgment, thereby improving the overall accuracy of skin cancer detection in primary care settings [33].

These insights collectively highlight the significant advancements and ongoing challenges in leveraging AI for skin cancer detection, underscoring the necessity for continued innovation and evaluation to refine these technologies and optimize their integration into clinical practice. By harnessing the power of AI to analyze vast datasets and discern subtle patterns, dermatologists can enhance their diagnostic prowess and mitigate the risks of misdiagnosis and underdiagnosis in skin cancer cases. In conclusion, the integration of AI and ML algorithms holds immense promise for advancing the field of skin cancer diagnosis. By leveraging innovative technologies and methodologies, researchers and healthcare professionals can enhance diagnostic accuracy, improve patient outcomes, and ultimately revolutionize how skin cancers are detected and managed. Collaborative efforts between AI systems and human experts are essential to harnessing the full potential of these cutting-edge technologies in the fight against skin cancer.

4. CONCLUSION

Skin cancer is a primary global health concern, causing over 60,000 deaths every year, especially in areas with high exposure to ultraviolet radiation. Artificial Intelligence (AI) and machine learning technologies have shown great promise in improving diagnostic capabilities. Research indicates that clinicians assisted by AI achieve sensitivity rates of 81.1% and specificity rates of 86.1%, compared to 74.8% and 81.5% for unassisted clinicians. AI algorithms have also outperformed dermatologists in various studies, demonstrating better diagnostic accuracy and the ability to identify a broader range of clinically relevant conditions. However, challenges such as the need for robust algorithms and high-quality data and the necessity for thorough validation of AI tools before widespread clinical use still need to be addressed. Collaboration between AI developers and healthcare professionals is crucial to ensure the effectiveness and safety of these technologies. Continuous innovation and evaluation are vital for improving AI applications in dermatology, with the ultimate goal of enhancing patient outcomes and reducing the strain on healthcare systems.

REFERENCES

- [1] I. G. A. I. Yogiswara, H. Saputra, and N. P. Ekawati, 'Karakteristik pasien kanker kulit non-melanoma di RSUP Sanglah pada periode tahun 2014 - 2018', *Intisari Sains Medis*, vol. 12, no. 2, pp. 691–694, Aug. 2021, doi: 10.15562/ism.v12i2.1080.
- [2] 'https://www.britannica.com/science/skin-cancer'.
- [3] R. N. P. Fauziyyah, M. Komariah, and Y. K. Herliani, 'Sunlight Exposure and Protection Behavior as Prevention of Skin Cancer in Nursing Students', *Indones. J. Cancer*, vol. 17, no. 1, p. 1, Mar. 2023, doi: 10.33371/ijoc.v17i1.921.
- [4] M. Z. Oktora, Y. Haiga, and N. Liana, 'Peningkatan Pengetahuan Masyarakat terhadap Pengaruh Paparan Sinar Matahari yang dapat Menyebabkan Kanker Kulit', *J. Pengabd. Masy. Kesehatan JURABDIKES*, vol. 1, no. 2, pp. 28–31, Dec. 2023, doi: 10.56260/jurabdikes.v1i2.105.
- [5] N. Arivazhagan *et al.*, 'Analysis of Skin Cancer and Patient Healthcare Using Data Mining Techniques', *Comput. Intell. Neurosci.*, vol. 2022, pp. 1–9, Sep. 2022, doi: 10.1155/2022/2250275.
- [6] Md. R. Islam, S. Akash, A. Rauf, and R. Sharma, 'Skin cancer from the perspective of public health concerns: etiology, transmission, diagnosis, treatment, and complications – correspondence', *Ann. Med. Surg.*, vol. 85, no. 5, pp. 2266–2267, May 2023, doi: 10.1097/MS9.0000000000000662.
- [7] S. Pandey and G. K. Shankhdhar, 'Skin cancer diagnosis using the deep learning advancements: a technical review', *Bull. Electr. Eng. Inform.*, vol. 13, no. 3, pp. 1847–1856, Jun. 2024, doi: 10.11591/eei.v13i3.5925.
- [8] G. Brancaccio, A. Balato, J. Malvey, S. Puig, G. Argenziano, and H. Kittler, 'Artificial Intelligence in Skin Cancer Diagnosis: A Reality Check', *J. Invest. Dermatol.*, vol. 144, no. 3, pp. 492–499, Mar. 2024, doi: 10.1016/j.jid.2023.10.004.
- [9] M. A. Hussien and A. H. H. Alasadi, 'A Review of Skin Cancer Detection: Traditional and Deep Learning-Based Techniques', *J. Univ. BABYLON Pure Appl. Sci.*, vol. 31, no. 2, pp. 253–262, Jun. 2023, doi: 10.29196/jubpas.v31i2.4682.
- [10] M. Naqvi, S. Q. Gilani, T. Syed, O. Marques, and H.-C. Kim, 'Skin Cancer Detection Using Deep Learning—A Review', *Diagnostics*, vol. 13, no. 11, p. 1911, May 2023, doi: 10.3390/diagnostics13111911.
- [11] M. L. Wei, M. Tada, A. So, and R. Torres, 'Artificial intelligence and skin cancer', *Front. Med.*, vol. 11, p. 1331895, Mar. 2024, doi: 10.3389/fmed.2024.1331895.
- [12] Prof. R. Jadhav, 'Skin Cancer Detection using Image Processing', *Int. J. Res. Appl. Sci. Eng. Technol.*, vol. 11, no. 5, pp. 4498–4503, May 2023, doi: 10.22214/ijraset.2023.52666.
- [13] M. Dildar *et al.*, 'Skin Cancer Detection: A Review Using Deep Learning Techniques', *Int. J. Environ. Res. Public Health*, vol. 18, no. 10, p. 5479, May 2021, doi: 10.3390/ijerph18105479.
- [14] M. Goyal, T. Knackstedt, S. Yan, and S. Hassanpour, 'Artificial intelligence-based image classification methods for diagnosis of skin cancer: Challenges and opportunities', *Comput. Biol. Med.*, vol. 127, p. 104065, Dec. 2020, doi: 10.1016/j.combiomed.2020.104065.
- [15] M. Joly-Chevrier, A. X.-L. Nguyen, L. Liang, M. Lesko-Krleza, and P. Lefrançois, 'The State of Artificial Intelligence in Skin Cancer Publications', *J. Cutan. Med. Surg.*.
- [16] 'Artificial intelligence for skin cancer detection and classification for clinical environment: a systematic review', *Front. Med.*.
- [17] O. T. Jones *et al.*, 'Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review', *Lancet Digit. Health*, vol. 4, no. 6, pp. e466–e476, Jun. 2022, doi: 10.1016/S2589-7500(22)00023-1.
- [18] I. Krakowski, 'Human-AI interaction in skin cancer diagnosis: a systematic review and meta-analysis', 2024.

- [19] D. M. Do, 'Use of an elastic-scattering spectroscopy and artificial intelligence device in the assessment of lesions suggestive of skin cancer: A comparative effectiveness study', vol. 14, 2024.
- [20] V. Mallikarjunaradhya and J. Mistry, 'The Optimized Analysis For Early Detection Of Skin Cancer Using Artificial Intelligence', vol. 11, no. 7, 2023.
- [21] I. Citrashanty and M. Wardiana, 'Artificial intelligence in skin cancer diagnosis: a literature review'.
- [22] Q. Liu, J. Zhang, and Y. Bai, 'Mapping the landscape of artificial intelligence in skin cancer research: a bibliometric analysis', *Front. Oncol.*
- [23] E. Triandini, S. Jayanatha, A. Indrawan, G. Werla Putra, and B. Iswara, 'Metode Systematic Literature Review untuk Identifikasi Platform dan Metode Pengembangan Sistem Informasi di Indonesia', *Indones. J. Inf. Syst.*, vol. 1, no. 2, p. 63, Feb. 2019, doi: 10.24002/ijis.v1i2.1916.
- [24] M. J. Page *et al.*, 'The PRISMA 2020 statement: an updated guideline for reporting systematic reviews', *BMJ*, p. n71, Mar. 2021, doi: 10.1136/bmj.n71.
- [25] 'SYSTEMATIC LITERATUR REVIEW DENGAN METODE PRISMA: DAMPAK TEKNOLOGI BLOCKCHAIN TERHADAP PERIKLANAN DIGITAL', *J. Ilm. M-Prog.*, vol. 14, no. 1, Jan. 2024, doi: 10.35968/m-pu.v14i1.1182.
- [26] Sukma Febrianti, 'Sustainability Finance Dan Green Investment: Literature Review Dengan Metode Prisma', *Manaj. J. Ekon.*, vol. 6, no. 1, pp. 95–106, May 2024, doi: 10.36985/manajemen.v6i1.1151.
- [27] V. D. Midasala, B. Prabhakar, J. Krishna Chaitanya, K. Srinivas, D. Eshwar, and P. M. Kumar, 'MFEUsLNet: Skin cancer detection and classification using integrated AI with multilevel feature extraction-based unsupervised learning', *Eng. Sci. Technol. Int. J.*, vol. 51, p. 101632, Mar. 2024, doi: 10.1016/j.jestch.2024.101632.
- [28] S. Gaube, I. Biebl, M. K. M. Engelmann, A.-K. Kleine, and E. Lerner, 'Comparing preferences for skin cancer screening: AI-enabled app vs dermatologist', *Soc. Sci. Med.*, vol. 349, p. 116871, May 2024, doi: 10.1016/j.socscimed.2024.116871.
- [29] R. N. Martin and J. Dinnes, 'AI-based smartphone apps for risk assessment of skin cancer need more evaluation and better regulation', *Br. J. Cancer*, vol. 124, no. 11, pp. 1749–1750, May 2021, doi: 10.1038/s41416-021-01302-3.
- [30] C. Barata *et al.*, 'A reinforcement learning model for AI-based decision support in skin cancer', *Nat. Med.*, vol. 29, no. 8, pp. 1941–1946, Aug. 2023, doi: 10.1038/s41591-023-02475-5.
- [31] K. P. Venkatesh, K. T. Kadakia, and S. Gilbert, 'Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA', *Npj Digit. Med.*, vol. 7, no. 1, p. 156, Jun. 2024, doi: 10.1038/s41746-024-01161-1.
- [32] M. Saeed, A. Naseer, H. Masood, S. U. Rehman, and V. Gruhn, 'The Power of Generative AI to Augment for Enhanced Skin Cancer Classification: A Deep Learning Approach', *IEEE Access*, vol. 11, pp. 130330–130344, 2023, doi: 10.1109/ACCESS.2023.3332628.
- [33] E. Jaklitsch, T. Thames, T. De Campos Silva, P. Coll, M. Oliviero, and L. K. Ferris, 'Clinical Utility of an AI-powered, Handheld Elastic Scattering Spectroscopy Device on the Diagnosis and Management of Skin Cancer by Primary Care Physicians', *J. Prim. Care Community Health*, vol. 14, p. 21501319231205979, Jan. 2023, doi: 10.1177/21501319231205979.
- [34] H. Marsden *et al.*, 'Effectiveness of an image analyzing AI-based Digital Health Technology to identify Non-Melanoma Skin Cancer and other skin lesions: results of the DERM-003 study', *Front. Med.*, vol. 10, p. 1288521, Oct. 2023, doi: 10.3389/fmed.2023.1288521.
- [35] N. Melarkode, K. Srinivasan, S. M. Qaisar, and P. Plawiak, 'AI-Powered Diagnosis of Skin Cancer: A Contemporary Review, Open Challenges and Future Research Directions', *Cancers*, vol. 15, no. 4, p. 1183, Feb. 2023, doi: 10.3390/cancers15041183.